Phase hub

Early Phase I clinical trial failures

Explore 614 stopped early phase i clinical trials with sponsors, indications, and stop-reason signals.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 14 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials614
Likely biological signals14
Shown below100

Dominant stop reasons

OPERATIONAL
347
OTHER/UNKNOWN
250
EFFICACY/FUTILITY
8
SAFETY
6
REGULATORY
3

Notable sponsors

Wake Forest University Health Sciences
14
Yale University
14
M.D. Anderson Cancer Center
12
Johns Hopkins University
10
University of Alabama at Birmingham
10

Related phases

Early Phase I
614

Crawlable stopped-trial records

Open Explore

Showing up to 100 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT07315503: An Open-label Study of GC012F in Rheumatoid Arthritis.

Early Phase I Rheumatoid Arthritis trial by Institute of Hematology & Blood Diseases Hospital, China. Stop reason: OPERATIONAL.

Due to the sponsor's adjustment of the research and development strategy for this clinical trial, this study was prematurely terminated, and no subjects were recruited for this study

NCT06932393: Exosomes for Hairloss Treatment

Early Phase I Hair Loss trial by Guangzhou Bio-gene Technology Co., Ltd. Stop reason: OTHER/UNKNOWN.

Per updated regulatory requirements, the site is ineligible to proceed. The clinical institution office has terminated the project.

NCT05270265: Safety and Immunogenicity of Pvs25-IMX313/Matrix-M1 Vaccine

Early Phase I Malaria, Vivax trial by University of Oxford. Stop reason: OPERATIONAL.

The study was terminated due to administrative delays in the approval of a substantial amendment to extend the shelf-life of Pvs25-IMX313. Regulatory approval was only received on 11 August 2023, after end of study visits had already been conducted.

NCT06516510: A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer

Early Phase I Metastatic Prostate Cancer trial by Blue Earth Therapeutics Ltd. Stop reason: EFFICACY/FUTILITY.

Based on data from the Interim Analysis, the study will not adequately inform the clinical development programme for Lutetium (177Lu) rhPSMA-10.1 injection in the way that the study was intended. There are no concerns regarding participant safety.

NCT05821374: Deucravacitinib in PG

Early Phase I Pyoderma Gangrenosum trial by Dartmouth-Hitchcock Medical Center. Stop reason: OPERATIONAL.

Issues with funding and IND holder

NCT05601492: Adherence to Otezla

Early Phase I Psoriasis trial by Wake Forest University Health Sciences. Stop reason: OPERATIONAL.

Terminated IRB approval 6/26/2024, study was never initiated or activated